67 related articles for article (PubMed ID: 28778350)
1. Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis.
Hernández-Alava M; Pudney S
J Health Econ; 2017 Sep; 55():139-152. PubMed ID: 28778350
[TBL] [Abstract][Full Text] [Related]
2. Mapping to Quality of Life and Capability Measures in Cataract Surgery Patients: From Cat-PROM5 to EQ-5D-3L, EQ-5D-5L, and ICECAP-O Using Mixture Modelling.
Dixon P; Hollingworth W; Sparrow J
MDM Policy Pract; 2020; 5(1):2381468320915447. PubMed ID: 32285008
[No Abstract] [Full Text] [Related]
3. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
4. How do EQ-5D-3L and EQ-5D-5L compare in a Swedish total hip replacement population?
Eneqvist T; Nemes S; Kärrholm J; Burström K; Rolfson O
Acta Orthop; 2020 Jun; 91(3):272-278. PubMed ID: 32237930
[TBL] [Abstract][Full Text] [Related]
5. Use of removable support boot versus cast for early mobilisation after ankle fracture surgery: cost-effectiveness analysis and qualitative findings of the Ankle Recovery Trial (ART).
Baji P; Barbosa EC; Heaslip V; Sangar B; Tbaily L; Martin R; Docherty S; Allen H; Hayward C; Marques EMR
BMJ Open; 2024 Jan; 14(1):e073542. PubMed ID: 38216176
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life across disease stages in patients with amyotrophic lateral sclerosis: results from a real-world survey.
Stenson K; Fecteau TE; O'Callaghan L; Bryden P; Mellor J; Wright J; Earl L; Thomas O; Iqbal H; Barlow S; Parvanta S
J Neurol; 2024 May; 271(5):2390-2404. PubMed ID: 38200398
[TBL] [Abstract][Full Text] [Related]
7. Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
Coughlan D; Arisa O; Thomson K; Yu G; Pearson F; Kernohan A; Gonzalez-Moral SG; Wallace S; Rice S
Pharmacoeconomics; 2024 Jan; 42(1):5-9. PubMed ID: 37796409
[No Abstract] [Full Text] [Related]
8. The effectiveness and cost-effectiveness of a group domestic abuse perpetrator programme: protocol for a randomised controlled trial.
Morgan K; Man MS; Bloomer R; Cochrane M; Cole M; Dheensa S; Eisenstadt N; Feder G; Gaunt DM; Leach R; Kandiyali R; Noble S; Peters TJ; Shirkey BA; Cramer H
Trials; 2023 Sep; 24(1):617. PubMed ID: 37770906
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
[TBL] [Abstract][Full Text] [Related]
10. Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study.
Hernández Alava M; Pudney S; Wailoo A
Pharmacoeconomics; 2023 Feb; 41(2):199-207. PubMed ID: 36449173
[TBL] [Abstract][Full Text] [Related]
11. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
12. Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review.
Keetharuth AD; Hussain H; Rowen D; Wailoo A
Health Qual Life Outcomes; 2022 Sep; 20(1):139. PubMed ID: 36171595
[TBL] [Abstract][Full Text] [Related]
13. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
[TBL] [Abstract][Full Text] [Related]
14. Health utilities and costs for neuromyelitis optica spectrum disorder.
Hughes DA; Bourke S; Jones A; Bhatt R; Huda S; Mutch K; Jacob A
Orphanet J Rare Dis; 2022 Apr; 17(1):159. PubMed ID: 35392962
[TBL] [Abstract][Full Text] [Related]
15. Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data.
Hernández-Alava M; Pudney S
Health Econ; 2022 Jun; 31(6):923-939. PubMed ID: 35229404
[TBL] [Abstract][Full Text] [Related]
16. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data.
Neilson AR; Jones GT; Macfarlane GJ; Pathan EM; McNamee P
Eur J Health Econ; 2022 Nov; 23(8):1357-1369. PubMed ID: 35113270
[TBL] [Abstract][Full Text] [Related]
17. Dose Correlation of
Lin W; Zheng M; Chen Y; He Q; Khoja A; Long M; Fan J; Hao Y; Fu C; Hu P; Wang K; Jiang J; Zhao X
Evid Based Complement Alternat Med; 2021; 2021():9933254. PubMed ID: 34484409
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life in Patients with Health Conditions in Lebanese Community Setting.
Dimassi H; Nasser SC; Issa A; Adrian SS; Hazimeh B
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444566
[TBL] [Abstract][Full Text] [Related]
19. A feasibility trial of an intervention in alcohol dependence for structured preparation before detoxification versus usual care: the SPADe trial results.
Kouimtsidis C; Houghton B; Gage H; Notley C; Maskrey V; Clark A; Holland R; Lingford-Hughes A; Punukollu B; Touray M; Duka T
Pilot Feasibility Stud; 2021 Jul; 7(1):148. PubMed ID: 34325743
[TBL] [Abstract][Full Text] [Related]
20. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
